πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11890354

Activatable antibodies that bind epidermal growth factor receptor and methods thereof

CytomX Therapeutics, Inc. Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11892450

Evaluation, assays and treatment of pKal-mediated disorders

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890359

Zirconia composition, partially sintered material and sintered material and methods for pr

KURARAY NORITAKE DENTAL INC. Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11892452

Disease-associated antigens and methods of use thereof

The Regents of the University of California Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890307

Compositions for fecal floral transplantation and methods for making and using them and de

Finch Therapeutics Holdings LLC Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11891431

Removal of serine proteases by treatment with finely divided silicon dioxide

Takeda Pharm Limited ceutical Company Limited Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890290

Topical treatment of wounds with statins and cholesterol for scar reduction

Northwestern University Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890306

Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for

Finch Therapeutics Holdings LLC Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890272

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890308

Compositions for fecal floral transplantation and methods for making and using them and de

Finch Therapeutics Holdings LLC Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890330

Endolysins active against Bacillus bacteria, pharmaceutical compositions, and methods rela

United States of America as represented by the Secretary of the Air Force Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890225

Devices and methods for slurry generation

MIRAKI INNOVATION THINK TANK LLC Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890339

Nipah virus immunogens and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890340

Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11891638

Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

Northwestern University Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11890344

One-step processing of hydrogels for mechanically robust and chemically desired features

The Board of Regents of the University of Texas System Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11891360

Glycosylated psilocybin derivatives and methods of using

Enveric Biosciences Canada Inc. Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11885861

3-dimensional representations of post-contrast enhanced brain lesions

The Board of Regents of the University of Texas System Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11885807

Method for depleting malignant T-cells

AUTOLUS LIMITED Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11885806

Method for depleting malignant T-cells

AUTOLUS LIMITED Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11885817

Biomarkers and methods for detection of seizures and epilepsy

Cognizance Biomarkers, LLC Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11884919

Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gen

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11884920

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11884925

Synthetic immunomodulation with a CRISPR super-repressor in vivo

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted